US20110245592A1

US20110245592A1 - Secretome Profile-Facilitated In Vitro Fertilization

Info

Publication number: US20110245592A1
Application number: US13/081,463
Authority: US
Inventors: William B. Schoolcraft; Mandy Katz-Jaffe; Susanna McReynolds
Original assignee: NATIONAL FOUNDATION FOR FERTILITY RESEARCH
Current assignee: FERTILITY LAB SCIENCES LLC
Priority date: 2010-04-06
Filing date: 2011-04-06
Publication date: 2011-10-06
Also published as: WO2011127214A2; EP3904885A1; US20170328913A1; AU2020286226B2; WO2011127214A3; CA3011100C; CA2795562A1; NZ771197A; US20190227075A1; EP2556376A2; AU2018203151B2; CA2795562C; ES2882325T3; BR112012025331A2; BR112012025331B1; AU2016202346B2; US9874572B2; AU2020286226A1; US9714950B2; EP3242136A2

Abstract

Secretome profiling improves the pregnancy success rate of in vitro fertilization processes, while reducing the risk of multiple births.

Description

RELATED APPLICATIONS

This application claims benefit of priority to U.S. Provisional Patent Application No. 61/321,448 filed Apr. 6, 2010, which is incorporated by reference to the same extent as though fully replicated herein.

SEQUENCE LISTING

This application includes a Sequence Listing, as set forth in an ASCII-compliant text file named “CCRMProtein_ST25.txt”, created on Apr. 6, 2011, and containing 2263 kilobytes, which is incorporated by reference to the same extent as though fully replicated herein.

BACKGROUND

1. Field of the Invention
The invention relates to the field of in vitro fertilization (IVF), which is a process by which mammalian egg cells are fertilized by sperm outside the womb. More particularly, evaluation of a secretome profile is used to enhance the pregnancy success rate when the fertilized egg is implanted into a patient's uterus.
2. Description of the Related Art
IVF infertility treatment offers infertile couples a chance to have a biologically related child. IVF may overcome female infertility due to problems of the fallopian tube or endometriosis. IVF also overcomes male infertility due to problems with sperm quality or quantity. The IVF process involves hormonally controlling the ovulatory process, removing eggs (termed ova) from the woman's ovaries and permitting the sperm to fertilize the eggs in a fluid medium. The fertilized egg, termed an embryo, is subsequently transferred to the patient's uterus with the intent of establishing a successful pregnancy. Due to expensive procedural costs, IVF is only attempted after the failure of less expensive fertility treatments.
FIG. 1 displays a schematic for mammalian blastocyst implantation. Mammalian embryo implantation is a complex and intricate process involving numerous biological changes at both the embryo and endometrial level. The interaction between the blastocyst and the endometrium is a function of both a receptive endometrial environment and a healthy blastocyst. A blastocyst failing to implant or an endometrium failing to sustain growth and differentiation will result in spontaneous abortion. The prior art teaches very little about the embryo's role in the events leading to the attachment of a viable blastocyst to a receptive uterine luminal epithelium.
IVF treatment begins with administration of hormonal medications to stimulate ovarian follicle production, such as gonadotropins hormones. The prevention of spontaneous ovulation involves using other hormones, such as GnRH antagonists or GnRH agonists that block the natural surge of luteinizing hormone. With adequate follicular maturation, administration of human chorionic gonadotropin hormone causes ovulation approximately 42 hours after the administration. However, the egg retrieval procedure takes place just prior to ovulation, in order to recover the eggs from the ovary. The egg retrieval proceeds using a transvaginal technique involving an ultrasound-guided needle that pierces the vaginal wall to reach the ovaries. After recovery of the follicles through the needle, the follicular fluid is provided to the IVF laboratory to identify eggs. Typically, the procedure retrieves between 10 and 30 eggs. The retrieval procedure takes approximately 20 minutes and is usually done under conscious sedation or general anesthesia.
For IVF, the fertilization of the egg (termed insemination) proceeds in the laboratory where the identified eggs and semen are usually incubated together in a culture media. The confirmation of fertilization proceeds by monitoring the eggs for cell division. For instance, a fertilized egg may show two pronuclei. In certain situations, such as low sperm count or motility, a single sperm may be injected directly into the egg using a method called intracytoplasmic sperm injection (ICSI). In another option known as gamete intrafallopian transfer, eggs are removed from the woman and placed in one of the fallopian tubes, along with the man's sperm. In this example, fertilization occurs within the women's body, a process termed in vivo fertilization.
Selected embryos are transferred to the patient's uterus through a thin, plastic catheter, which goes through the vagina and cervix. Typically, transfer of 6-8 cell stage embryos to the uterus occurs three days after embryo retrieval. Alternatively, embryos can be placed into an extended culture system with a transfer done at the blastocyst stage at approximately five days post-retrieval. Blastocyst stage transfers often result in higher pregnancy rates. Additionally, embryonic cryopreservation, or the storage of embryos in a frozen state, is feasible until uterine transfer. For example, the first term pregnancy derived from a frozen human embryo was reported in 1984.
Despite progressively improving IVF pregnancy rates, the majority of transferred human embryos result in implantation failure. For example, Canadian clinics reported an average pregnancy rate of 35% for one cycle, but a live birth rate of only 27% in 2006. Moreover, implantation success rates may decrease with the increasing maternal age, if donor eggs are not used. Various factors are associated with implantation failure, including embryo chromosome aneuploidies related to advanced maternal age and maternal factors such as endometrium response failure to hormone regulation.
To overcome low implantation success rate, multiple embryos are commonly transferred during a single IVF procedure. The process for selecting embryos for transfer often involves grading methods developed in individual laboratories to judge oocyte and embryo quality. An arbitrary embryo score, involving the number and quality of embryos, may reveal the probability of pregnancy success post-transfer. For example, an embryologist may grade embryos using morphological qualities including the number of cells, clearness of cytoplasm, evenness of growth and degree of fragmentation. However, embryo selection based on morphological qualities is not precise. Often, several embryos selected for these general qualities are implanted to improve the chance of pregnancy. The number of embryos transferred depends upon the number available, the age of the woman and other health and diagnostic factors.
The transfer of multiple embryos, however, often results in multiple pregnancies, a major complication of IVF. In general, multiple pregnancies, specifically, more than twins, hold maternal and fetal risks. For example, multiple births are associated with increased risk of pregnancy loss, neonatal morbidity, obstetrical complications, and prematurity with potential for long term damage. Some countries implemented strict limits on the number of transferred embryos to reduce the risk of high-order multiples (e.g., triplets or more). However, these limitations are not universally followed or accepted.

SUMMARY

In one embodiment, a system for enhancing the pregnancy success rate of in vitro fertilization includes a means for determining the secretome profile of an embryo to identify proteins, polypeptides, oligopeptides or protein fragments implicated in implantation success and a means for recommending whether to implant the embryo, such as a blastocyst, on the basis of the secretome profile.
The CDC data from 2006 shows that use of donor eggs in a 40 year old woman will result in a live birth 54% of the time. This compares to 20.6% using the woman's own eggs. Thus, an opportunity exists for the instrumentalities of this disclosure to facilitate success rates approximating the use of donor eggs when using one's own eggs, and may even permit higher success rates due to better selection of viable embryos.
In an embodiment, a system is provided for enhancing the pregnancy success rate of in vitro fertilization. The system includes an electronic system to configured to gather secretome data as a secretome profile of an embryo by quantitating proteins implicated in implantation success. A model is provided for use in recommending whether to implant the embryo on the basis of this secretome profile. The secretome date may be, for example, provided by use of mass spectroscopy or ELISA measurements.
According to one aspect of the system, the secretome profile may be provided by using proteins as embryo secretions in culture media that may be linked to changed odds of implantation success, for example, as may be found in one or more sequences found in SEQ ID Nos. 1-404. The sequences of SEQ ID Nos. 261-404 are preferred for this use. Particularly preferred are the sequences of SEQ ID Nos. 310, 311, 313, 317, 318, 319, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 345, 346, 347, 348, 349, 350, 368, 371, 374, 383, 391, 397, 398, 399, 402, 403, and 404. The sequences of SEQ ID Nos. 310, 311, 313, 318, 319, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 345, 346, 347, 348, 349, 350, 368, 371, 374, 391, 397, 398, 399, 402, 403, and 404 are associated with increased odds of implantation success, whereas those of SEQ ID Nos. 317 and 383 are associated with failure or aneuploidy.
In an embodiment, a method of in vitro fertilization entails determining the secretome profile of a candidate embryo by use of these sequences to ascertain proteins implicated in implantation success. This provides data that may be submitted to a model that associates one or more of these proteins with changes odds of implantation success or failure. A recommendation for implantation of the embryo may then be provided based upon the modeling outcome. The embryo may be conditionally implanted on the basis of the recommendation.
In an embodiment, there is an improved ELISA assay kit with a plurality of microwells for the quantitation of protein content in a sample. The microwells are constructed and arranged to quantitate for a plurality of proteins selected from these sequences.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a diagram illustrating the process blastocyst implantation.

FIG. 2 is a table that illustrates the success rates from donor oocyte IVF cycles.

FIG. 3 is a flow chart for a method of developing and using a predictive model that may be used to assess embryo viability as a candidate for use in an IVF implantation procedure.

FIG. 4 shows a system that analyzes the secretome of an embryo to assess viability.

DETAILED DESCRIPTION

The following definitions are provided to facilitate understanding of certain terms used herein and are not meant to limit the scope of the present disclosure.
The term “secretome panel” refers to a collection of individual proteins, polypeptides, oligopeptides or protein fragments that are differentially expressed and secreted by an embryo. The proteins, polypeptides, oligopeptides or protein fragments of the secretome panel are selected based on predictions of developmental competence and implantation potential of an embryo.
The term “spent media” refers to media surrounding an embryo that accumulates proteins secreted from the embryo.
The term “secretome profiling” refers to qualitative and quantitative analysis of a secretome panel collected from spent media.
There will now be shown and described a system for enhancing the pregnancy success rate of in vitro fertilization involving non-invasive secretome profiling of an embryo. Secretome profiling may be performed on embryos at differing embryonic developmental stages, such as day one through day six embryos.
Non-limiting examples of proteins comprising the secretome panel include proteins involved in amino acid metabolism, lipid metabolism, carbohydrate metabolism, signal transduction, apoptosis, transcription and combinations thereof. In one example, an embryo secretes a protein that is involved in amino acid metabolism, thereby indicating potential for successful embryo implantation. In another example, an embryo secretes a protein that is involved in apoptosis, thereby indicating a reduced potential for successful blastocyst implantation. Nonlimiting examples of the number of proteins comprising the secretome panel includes ≧250 proteins, ≧100 proteins, ≧50 proteins, ≧20 proteins or ≧10 proteins.
Secretome profiling involves assessment of a secretome panel. Secretome profiling is a noninvasive method for predicting developmental competence and viability of an embryo. Comparison of secretome profiles between developing embryos and degenerating embryos, both at the same developmental stage, reveals significant differences in protein expression. Moreover, secretome profiling provides a molecular perspective of the functioning biochemical pathways present during embryo development. A noninvasive secretome profiling assay correlates embryonic secretome to embryonic viability, thereby facilitating single embryo transfer during in vitro fertilization.
FIG. 2 highlights the importance of embryo developmental competence by showing high success rates from donor oocyte IVF cycles using young reproductive age oocytes transferred to an advanced maternal age endometrium. The data is provided for a Colorado clinic from 2004-2009 including outcomes for over 1000 donor oocyte cycles. These results demonstrate a 66.6% implantation rate for IVF recipients with an average endometrial age of 40.6 years and donor oocytes with an average age of 26.6 years.
In one embodiment, secretome profiling occurs by assessing a secretome panel via Enzyme-Linked Immunosorbent Assay (ELISA). In another embodiment, secretome profiling proceeds by assessing a secretome panel via mass spectrometry.
Non-limiting examples of solid-state substrates used in ELISA include microwell plates, such as 96-well plates, 384-well plates and 8-well strips, microarray slides and nitrocellulose membranes. In one embodiment, glass microarray surfaces contain chemical functional groups such as epoxy, amine or aldehyde. In one embodiment, microwell plate material comprises polystyrene.
The term “capture antibody” refers to an antibody secured, either covalently or non-covalently, to a solid-state substrate. The capture antibody recognizes and binds to a specific antigen such as a protein, a polypeptide, an oligopeptide, a protein fragment, a carbohydrate or a small molecule. In one example, a solid-state substrate is functionalized with capture antibodies by passive adsorption or by specific binding. For example, specific binding of capture antibodies may occur using biotinylated capture antibodies and streptavidin-coated solid-state substrates. In another example, solid-state substrates are functionalized with antigens via passive adsorption.
Non-limiting examples of ELISA types include direct, indirect, competitive, and sandwich. In one example, proteins from the secretome panel are detected on a solid-state substrate using either a primary labeled antibody or a secondary labeled antibody. In another example, proteins from the secretome panels are detecting using a sandwich ELISA wherein a protein from the secretome panel is bound between two primary antibodies, namely the capture antibody and the detection antibody. Non-limiting examples of antibody labels include enzymes and fluororphores. In one embodiment, an enzyme that is conjugated to a detection antibody binds to a substrate producing either a chromogenic, fluorescent or chemiluminescent signal that is proportional to the quantity of protein from the secretome panel.
FIG. 3 shows a method 300 implementing the concepts described above to identify those embryos having the greatest chanced for implantation success rates. Step 302 entails ascertaining the secretome of proteins secreted into culture medium by an egg, blastocyst or developing embryo (hereinafter “embryo”) that has been previously fertilized by methods known to the art. Step 302 may be performed at any time, including before an egg is fertilized or immediately thereafter. More typical times to sample the media include form one to five days after fertilization occurs. Step 302 is preferably conducted before step 304, but samples of the culture medium may be frozen for later analysis. The embryo is then used 304 in an IVF procedure attempting to implant the embryo in a woman who desires to have a baby. The implantation successes and failures are monitored 306 to collect data relating the successes and failures to one or more proteins of the secretome. Once a sufficient number of instances have transpired 308 to provide for statistical significance, the proteins are mapped 310 to the instances of success and failure. The exact manner of mapping is not of particular importance, as there a number of biostatistical analysis software products are commercially available. For example, this may be done using the JMP® 9 packages from SAS of Cary, N.C. to implement methods as taught by Zar, Biostatistical Analysis, 5th Ed., Prentice Hall (2007) to map the secretome profiles using also time as a variable. The mapping may be multivariate, or by an artificially intelligent algorithm, such as a neural network. This model may be then used 312 as a predictive tool to select embryos for implantation based upon their secretome profile. This is done by analyzing 314 the secretome of candidate embryos for implantation with use of the model to predict implantation success or failure. One or more of the selected embryos are then implanted 316
FIG. 4 shows an analytical system 400 that may be used in step 314 according to one embodiment. A specimen 402 contains a sample of culture medium that is collected for secretome analysis as described above. By way of example, this specimen may contain culture medium in the form of a single or multi-well ELISA assay, or in a form that has bee pre-processed for mass spectroscopy analysis. A corresponding measurement device 404 obtains primary measurements from the specimen 402. The measurements are representative of one or more proteins in the secretome that have been mapped to incidences of implantation success of failure. The model for this mapping is provided in step 312 of method 300 and resides on analyzer 406, which may be a computer operating on program instructions. The analyzer 406 receives signals from the measurement device 404 and interprets these by computational analysis according to the model then provides the results of computational analysis to an output device 408, which may be printer or an optical display. The various components of system 400 may be partially integrated, such as by combining the measurement device 404, analyzer 406, and output device 408 into one integrated system.
It will be appreciated that perceptive use of the instrumentalities described herein may result in a better selection of healthy embryos, such as blastocysts, for implantation. Thus, fewer blastocysts need to be implemented, such that there is lower risk of multiple pregnancies while achieving a higher overall pregnancy success rate.
The following descriptions will show and describe, by way of non-limiting examples, a process for improving pregnancy success rates with lower incidence of multiple births. The following examples describe secretome profiling of spent media from human blastocysts to provide implantation recommendation. It is to be understood that these examples are provided by way of illustration and should not be unduly construed to limit the scope of what is disclosed herein.

Example 1

Secretome Profiling of Human Embryos Using Mass Spectrometry

The following nonlimiting example teaches by way of illustration, not by limitation, secretome profiling of a human embryo using mass spectrometry (MS). Human cleavage-stage embryos were cultured in 10 μL drops of G1 supplemented with 2.5 mg/mL recombinant albumin under oil at 37° C., 6% CO₂, 5% O₂for 24 hours. The embryos were washed twice in G2 culture media and further cultured in 10 μL drops of G2 supplemented with 2.5 mg/mL recombinant albumin under oil at 37° C., 6% CO₂, 5% O₂for 48 hours with a fresh drop of G2 media added after 24 hours. Spent media samples of blastocysts were transferred into 0.65 mL Eppendorf tubes. Control groups comprised media cultured and collected under the same conditions but without embryos.
Micro-drops of spent media were depleted of human serum albumin (HSA) using Cibracron Blue Activated SwellGel Discs (Themo Fisher Scientific, Rockford, Ill.). The proteins in the spent media were separated by 1D gel electrophoresis (Invitrogen, Carlsbad, Calif.), followed by Coomassie staining. Twenty five individual bands were cut out from each sample lane and a standard in-gel digestion protocol was used based on previously used methods ((1.) Rosenfeld, J., Capdevielle, J., Guillemot, J. C. & Ferrara, P. In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis. Anal. Biochem. 203, 173-179 (1992), (2.) Hellman, U., Wernstedt, C., Gonez, J. & Heldin, C. H. Improvement of an “In-Gel” digestion procedure for the micropreparation of internal protein fragments for amino acid sequencing. Anal. Biochem. 224, 451-455 (1995)). Iodoacteamide (IAM) was used for cysteine alkylation. The samples were analyzed on a LTQ-FT Ultra Hybrid Mass Spectrometer (Thermo/Finnigan; Waltham, Mass.) with a method based on a previously described protocol from Hansen et al., (Hansen KC, Kiemele L, Maller O, O'Brien J, Shankar A, Formetti J, Schedin P. An in-solution ultrasonication-assisted digestion method for improved extracellular matrix proteome coverage. Mol Cell Proteomics. 8(7):1648-57 (2009)).
Spent media samples were analyzed on a LTQ-FT Ultra Hybrid Mass Spectrometer (Thermo/Finnigan; Waltham, Mass.). Peptide desalting and separation was achieved using a dual capillary/nano pump HPLC system (Agilent 1200, Palo Alto, Calif.). On this system 8 μL of spent media sample was loaded onto a trapping column (ZORBAX 300SB-C18, dimensions 5×0.3 mm 5 μm) and washed with 5% acetonitrile (ACN), 0.1% formic acid (FA) at a flow rate of 15 μL/min for 5 minutes. At this time, the trapping column was put online with the nano-pump at a flow rate of 350 nL/min. An 85 minute gradient, from 8% ACN to 40% ACN, was used to separate the peptides. The column was made from an in-house pulled 360/100 nm (outer/inner diameter) fused silica capillary packed with Jupiter C18 resin (Penomenex; Torrance, Calif.). The column was kept at a constant 40° C. using an in-house built column heater. Data acquisition was performed using the instrument supplied Xcalibur (version 2.0.6) software. The LC runs were monitored in positive ion mode by sequentially recording survey MS scans (m/z 400-2000), in the ICR cell, while three MS²were obtained in the ion trap via CID for the most intense ions. After two acquisitions of a given ion within 45 seconds, the ion was excluded for 150 seconds.
For data analysis, The Raw Distiller program (UCSF) was used to create a de-isotoped centroided peak lists from the raw spectra into the mascot format using the default settings. The peak lists were searched against the SwissProt Human database (51.6, Homo sapiens 15720 sequences) using Mascot™ server (Version 2.2, Matrix Science, Boston, Mass.). The search parameters are the same as those followed in Hansen et al., (Hansen K C, Kiemele L, Maller O, O'Brien J, Shankar A, Formetti J, Schedin P. An in-solution ultrasonication-assisted digestion method for improved extracellular matrix proteome coverage. Mol Cell Proteomic. 8(7): 1648-57 (2009)). The Mascot results were loaded into Scaffold (v 2.06) and the runs were compared.
In one embodiment, MS analysis of spent media reveals a secretome panel of 261 individual proteins (Table 1). In one example, secretome profiling using the secretome panel of 261 proteins (Table 1), as analyzed by MS, identifies the potential for developmental competence and implantation success of a human embryo.
In one embodiment, analysis of spent media via MS reveals a secretome panel of 37 individual proteins (Table 2). Secretome profiling via MS of 37 individual proteins (Table 2) from spent media of human embryos correlates with embryonic viability and euploidy. The term “euploidy” refers to having a chromosome number that is an exact multiple of the haploid number for a human embryo, namely 23 pairs of chromosomes.
In Tables 1 and 2 below, the entries for “Entry Name” and “Accession Number” refer to identifiers for published sequence data that is stored in bioinformatic databases including the Uniprot Knowledgebase, Swiss-Prot and TrEMBL. The information is made freely available to the world and is coordinated by the Swiss Institute of Bioinformatics, which is centrally administered in Lausanne, Switzerland with offices in Bern, Geneva and Zurich. The sequence information represented by these identifiers together with the representative publications is hereby incorporated by reference to the same extent as though fully replicated herein. For those proteins having isoforms, the sequences for Table 1 include consensus sequences for the primary isoforms, while sequences for Table 2 include also all other isoforms available at the time of filing.

TABLE 1

Proteins identified in spent media of human embryos.

			Protein
SEQ ID			Molecular	Accession
NO.	Protein Name	Entry Name	Weight	Number	Taxonomy

1	Serum albumin	ALBU_HUMAN	69	kDa	P02768	Homo sapiens
2	Serotransferrin	TRFE_HUMAN	77	kDa	P02787	Homo sapiens
3	Haptoglobin	HPT_HUMAN	45	kDa	P00738	Homo sapiens
4	Alpha-1-antitrypsin	A1AT_HUMAN	47	kDa	P01009	Homo sapiens
5	Alpha-2-macroglobulin	A2MG_HUMAN	163	kDa	P01023	Homo sapiens
6	Hemopexin	HEMO_HUMAN	52	kDa	P02790	Homo sapiens
7	Apolipoprotein A-I	APOA1_HUMAN	31	kDa	P02647	Homo sapiens
8	Ceruloplasmin	CERU_HUMAN	122	kDa	P00450	Homo sapiens
9	Vitamin D-binding protein	VTDB_HUMAN	53	kDa	P02774	Homo sapiens
10	Alpha-1-antichymotrypsin	AACT_HUMAN	48	kDa	P01011	Homo sapiens
11	Plasma protease C1 inhibitor	IC1_HUMAN	55	kDa	P05155	Homo sapiens
12	Alpha-1B-glycoprotein	A1BG_HUMAN	54	kDa	P04217	Homo sapiens
13	Hemoglobin subunit beta	HBB_HUMAN	16	kDa	P68871	Homo sapiens
14	Antithrombin-III	ANT3_HUMAN	53	kDa	P01008	Homo sapiens
15	Afamin	AFAM_HUMAN	69	kDa	P43652	Homo sapiens
16	Angiotensinogen	ANGT_HUMAN	53	kDa	P01019	Homo sapiens
17	Transthyretin	TTHY_HUMAN	16	kDa	P02766	Homo sapiens
18	Inter-alpha-trypsin inhibitor heavy	ITIH4_HUMAN	103	kDa	Q14624	Homo sapiens
	chain H4
19	Complement factor B	CFAB_HUMAN	86	kDa	P00751	Homo sapiens
20	Hemoglobin subunit alpha	HBA_HUMAN	15	kDa	P69905	Homo sapiens
21	Ig alpha-1 chain C region	IGHA1_HUMAN	38	kDa	P01876	Homo sapiens
22	Ig gamma-1 chain C region	IGHG1_HUMAN	36	kDa	P01857	Homo sapiens
23	Heparin cofactor 2	HEP2_HUMAN	57	kDa	P05546	Homo sapiens
24	Ig gamma-2 chain C region	IGHG2_HUMAN	36	kDa	P01859	Homo sapiens
25	Ig kappa chain C region	KAC_HUMAN	12	kDa	P01834	Homo sapiens
26	N-acetylmuramoyl-L-alanine	PGRP2_HUMAN	62	kDa	Q96PD5	Homo sapiens
	amidase
27	Alpha-2-HS-glycoprotein	FETUA_HUMAN	39	kDa	P02765	Homo sapiens
28	Kininogen-1	KNG1_HUMAN	72	kDa	P01042	Homo sapiens
29	Zinc-alpha-2-glycoprotein	ZA2G_HUMAN	34	kDa	P25311	Homo sapiens
30	Thyroxine-binding globulin	THBG_HUMAN	46	kDa	P05543	Homo sapiens
31	Corticosteroid-binding globulin	CBG_HUMAN	45	kDa	P08185	Homo sapiens
32	Attractin	ATRN_HUMAN	159	kDa	O75882	Homo sapiens
33	Pregnancy zone protein	PZP_HUMAN	164	kDa	P20742	Homo sapiens
34	Alpha-2-antiplasmin	A2AP_HUMAN	55	kDa	P08697	Homo sapiens
35	Vitronectin	VTNC_HUMAN	54	kDa	P04004	Homo sapiens
36	Ig lambda chain C regions	LAC_HUMAN	11	kDa	P01842	Homo sapiens
37	Apolipoprotein A-II	APOA2_HUMAN	11	kDa	P02652	Homo sapiens
38	Apolipoprotein C-III	APOC3_HUMAN	11	kDa	P02656	Homo sapiens
39	Insulin-like growth factor-binding	ALS_HUMAN	66	kDa	P35858	Homo sapiens
	protein complex acid labile chain
40	Complement C3	CO3_HUMAN	187	kDa	P01024	Homo sapiens
41	Complement C4-B	CO4B_HUMAN	193	kDa	P0C0L5	Homo sapiens
42	Serum paraoxonase/arylesterase 1	PON1_HUMAN	40	kDa	P27169	Homo sapiens
43	Plasma retinol-binding protein	RETBP_HUMAN	23	kDa	P02753	Homo sapiens
44	Carboxypeptidase N subunit 2	CPN2_HUMAN	61	kDa	P22792	Homo sapiens
45	Beta-2-glycoprotein 1	APOH_HUMAN	38	kDa	P02749	Homo sapiens
46	Inter-alpha-trypsin inhibitor heavy	ITIH2_HUMAN	106	kDa	P19823	Homo sapiens
	chain H2
47	Clusterin	CLUS_HUMAN	52	kDa	P10909	Homo sapiens
48	Protein AMBP	AMBP_HUMAN	39	kDa	P02760	Homo sapiens
49	Ig heavy chain V-III region BRO	HV305_HUMAN	13	kDa	P01766	Homo sapiens
50	Dynactin subunit 2	DCTN2_HUMAN	44	kDa	Q13561	Homo sapiens
51	Inter-alpha-trypsin inhibitor heavy	ITIH1_HUMAN	101	kDa	P19827	Homo sapiens
	chain H1
52	Complement C2	CO2_HUMAN	83	kDa	P06681	Homo sapiens
53	Serum amyloid P-component	SAMP_HUMAN	25	kDa	P02743	Homo sapiens
54	Lamin-A/C	LMNA_HUMAN	74	kDa	P02545	Homo sapiens
55	Phosphatidylinositol-glycan-specific	PHLD1_HUMAN	92	kDa	P80108	Homo sapiens
	phospholipase D
56	Alpha-1-acid glycoprotein 1	A1AG1_HUMAN	24	kDa	P02763	Homo sapiens
57	Pigment epithelium-derived factor	PEDF_HUMAN	46	kDa	P36955	Homo sapiens
58	Apolipoprotein C-I	APOC1_HUMAN	9	kDa	P02654	Homo sapiens
59	Transcription intermediary factor 1-	TIF1B_HUMAN	89	kDa	Q13263	Homo sapiens
	beta
60	Leucine-rich alpha-2-glycoprotein	A2GL_HUMAN	38	kDa	P02750	Homo sapiens
61	Lumican	LUM_HUMAN	38	kDa	P51884	Homo sapiens
62	Ig kappa chain V-III region SIE	KV302_HUMAN	12	kDa	P01620	Homo sapiens
63	Actin, cytoplasmic 1	ACTB_HUMAN	42	kDa	P60709	Homo sapiens
64	Apolipoprotein E	APOE_HUMAN	36	kDa	P02649	Homo sapiens
65	Kallistatin	KAIN_HUMAN	49	kDa	P29622	Homo sapiens
66	Myosin-15	MYH15_HUMAN	225	kDa	Q9Y2K3	Homo sapiens
67	Carboxypeptidase B2	CBPB2_HUMAN	48	kDa	Q96IY4	Homo sapiens
68	Serum amyloid A-4 protein	SAA4_HUMAN	15	kDa	P35542	Homo sapiens
69	Cholinesterase	CHLE_HUMAN	68	kDa	P06276	Homo sapiens
70	Apolipoprotein D	APOD_HUMAN	21	kDa	P05090	Homo sapiens
71	Tubulin beta-2C chain	TBB2C_HUMAN	50	kDa	P68371	Homo sapiens
72	Haptoglobin-related protein	HPTR_HUMAN	39	kDa	P00739	Homo sapiens
73	Hemoglobin subunit delta	HBD_HUMAN	16	kDa	P02042	Homo sapiens
74	Ig kappa chain V-IV region Len	KV402_HUMAN	13	kDa	P01625	Homo sapiens
75	Ig alpha-2 chain C region	IGHA2_HUMAN	37	kDa	P01877	Homo sapiens
76	Proteoglycan 4	PRG4_HUMAN	151	kDa	Q92954	Homo sapiens
77	Histone H2A type 1-D	H2A1D_HUMAN	14	kDa	P20671	Homo sapiens
78	Biotinidase	BTD_HUMAN	61	kDa	P43251	Homo sapiens
79	Carboxypeptidase N catalytic chain	CBPN_HUMAN	52	kDa	P15169	Homo sapiens
80	Plasma kallikrein	KLKB1_HUMAN	71	kDa	P03952	Homo sapiens
81	Ig kappa chain V-II region TEW	KV204_HUMAN	12	kDa	P01617	Homo sapiens
82	Apolipoprotein C-II	APOC2_HUMAN	11	kDa	P02655	Homo sapiens
83	DNA-dependent protein kinase	PRKDC_HUMAN	469	kDa	P78527	Homo sapiens
	catalytic subunit
84	Heterogeneous nuclear	HNRL1_HUMAN	96	kDa	Q9BUJ2	Homo sapiens
	ribonucleoprotein U-like protein 1
85	Apolipoprotein B-100	APOB_HUMAN	516	kDa	P04114	Homo sapiens
86	Heterogeneous nuclear	ROA2_HUMAN	37	kDa	P22626	Homo sapiens
	ribonucleoproteins A2/B1
87	Tubulin alpha-ubiquitous chain	TBAK_HUMAN	50	kDa	P68363	Homo sapiens
88	Gelsolin	GELS_HUMAN	86	kDa	P06396	Homo sapiens
89	Tetranectin	TETN_HUMAN	23	kDa	P05452	Homo sapiens
90	Alpha-1-acid glycoprotein 2	A1AG2_HUMAN	24	kDa	P19652	Homo sapiens
91	Ig heavy chain V-III region GAL	HV320_HUMAN	13	kDa	P01781	Homo sapiens
92	IgGFc-binding protein	FCGBP_HUMAN	572	kDa	Q9Y6R7	Homo sapiens
93	Lactotransferrin	TRFL_HUMAN	78	kDa	P02788	Homo sapiens
94	Histone H4	H4_HUMAN	11	kDa	P62805	Homo sapiens
95	Glutathione peroxidase 3	GPX3_HUMAN	26	kDa	P22352	Homo sapiens
96	Histone H2B type 1-M	H2B1M_HUMAN	14	kDa	Q99879	Homo sapiens
97	Apolipoprotein M	APOM_HUMAN	21	kDa	O95445	Homo sapiens
98	E3 SUMO-protein ligase RanBP2	RBP2_HUMAN	358	kDa	P49792	Homo sapiens
99	Ig kappa chain V-I region EU	KV106_HUMAN	12	kDa	P01598	Homo sapiens
100	Ig kappa chain V-I region Lay	KV113_HUMAN	12	kDa	P01605	Homo sapiens
101	Dermcidin OS = Homo sapiens	DCD_HUMAN	11	kDa	P81605	Homo sapiens
102	Leucine-rich repeats and	LRIG2_HUMAN	119	kDa	O94898	Homo sapiens
	immunoglobulin-like domains
	protein 2
103	Protein S100-A8	S10A8_HUMAN	11	kDa	P05109	Homo sapiens
104	Glyceraldehyde-3-phosphate	G3P_HUMAN	36	kDa	P04406	Homo sapiens
	dehydrogenase
105	Myosin-9	MYH9_HUMAN	227	kDa	P35579	Homo sapiens
106	Ig kappa chain V-III region VG	KV309_HUMAN	13	kDa	P04433	Homo sapiens
	(Fragment)
107	Monocyte differentiation antigen	CD14_HUMAN	40	kDa	P08571	Homo sapiens
	CD14
108	Heterogeneous nuclear	HNRH1_HUMAN	49	kDa	P31943	Homo sapiens
	ribonucleoprotein H
109	ATP-dependent DNA helicase 2	KU70_HUMAN	70	kDa	P12956	Homo sapiens
	subunit 1
110	Protein TFG	TFG_HUMAN	43	kDa	Q92734	Homo sapiens
111	Coagulation factor XII	FA12_HUMAN	68	kDa	P00748	Homo sapiens
112	Filaggrin-2	FILA2_HUMAN	248	kDa	Q5D862	Homo sapiens
113	Prothrombin	THRB_HUMAN	70	kDa	P00734	Homo sapiens
114	Sex hormone-binding globulin	SHBG_HUMAN	44	kDa	P04278	Homo sapiens
115	Heat shock cognate 71 kDa protein	HSP7C_HUMAN	71	kDa	P11142	Homo sapiens
116	Histidine-rich glycoprotein	HRG_HUMAN	60	kDa	P04196	Homo sapiens
117	Heterogeneous nuclear	ROA3_HUMAN	40	kDa	P51991	Homo sapiens
	ribonucleoprotein A3
118	Ig kappa chain V-III region B6	KV301_HUMAN	12	kDa	P01619	Homo sapiens
119	Testis-expressed sequence 15	TEX15_HUMAN	315	kDa	Q9BXT5	Homo sapiens
	protein
120	Polyadenylate-binding protein 1	PABP1_HUMAN	71	kDa	P11940	Homo sapiens
121	Lipopolysaccharide-binding protein	LBP_HUMAN	53	kDa	P18428	Homo sapiens
122	Lamina-associated polypeptide 2,	LAP2A_HUMAN	75	kDa	P42166	Homo sapiens
	isoform alpha
123	Desmoplakin	DESP_HUMAN	332	kDa	P15924	Homo sapiens
124	Protein S100-A9	S10A9_HUMAN	13	kDa	P06702	Homo sapiens
125	Far upstream element-binding	FUBP2_HUMAN	73	kDa	Q92945	Homo sapiens
	protein 2
126	Platelet glycoprotein Ib alpha chain	GP1BA_HUMAN	69	kDa	P07359	Homo sapiens
127	Zinc finger and SCAN domain-	ZSC29_HUMAN	97	kDa	Q8IWY8	Homo sapiens
	containing protein 29
128	Heterogeneous nuclear	HNRH3_HUMAN	37	kDa	P31942	Homo sapiens
	ribonucleoprotein H3
129	Histone H3.3	H33_HUMAN	15	kDa	P84243	Homo sapiens
130	Stress-70 protein, mitochondrial	GRP75_HUMAN	74	kDa	P38646	Homo sapiens
131	Ig kappa chain V-I region AG	KV101_HUMAN	12	kDa	P01593	Homo sapiens
132	Elongation factor 1-alpha 1	EF1A1_HUMAN	50	kDa	P68104	Homo sapiens
133	RNA-binding protein FUS	FUS_HUMAN	53	kDa	P35637	Homo sapiens
134	DNA repair and recombination	RA54B_HUMAN	103	kDa	Q9Y620	Homo sapiens
	protein RAD54B
135	Hornerin	HORN_HUMAN	282	kDa	Q86YZ3	Homo sapiens
136	Tubulin beta chain	TBB5_HUMAN	50	kDa	P07437	Homo sapiens
137	Heterogeneous nuclear	HNRPC_HUMAN	34	kDa	P07910	Homo sapiens
	ribonucleoproteins C1/C2
138	RecQ-mediated genome instability	RMI1_HUMAN	70	kDa	Q9H9A7	Homo sapiens
	protein 1
139	Desmocollin-1	DSC1_HUMAN	100	kDa	Q08554	Homo sapiens
140	Xaa-Pro dipeptidase	PEPD_HUMAN	55	kDa	P12955	Homo sapiens
141	Junction plakoglobin	PLAK_HUMAN	82	kDa	P14923	Homo sapiens
142	U3 small nucleolar RNA-associated	UT14C_HUMAN	87	kDa	Q5TAP6	Homo sapiens
	protein 14 homolog C
143	Obscurin	OBSCN_HUMAN	868	kDa	Q5VST9	Homo sapiens
144	Elongation factor Tu, mitochondrial	EFTU_HUMAN	50	kDa	P49411	Homo sapiens
145	Heterogeneous nuclear	HNRPF_HUMAN	46	kDa	P52597	Homo sapiens
	ribonucleoprotein F
146	Desmoglein-1	DSG1_HUMAN	114	kDa	Q02413	Homo sapiens
147	Heterogeneous nuclear	ROA1_HUMAN	39	kDa	P09651	Homo sapiens
	ribonucleoprotein Al
148	ELAV-like protein 1	ELAV1_HUMAN	36	kDa	Q15717	Homo sapiens
149	Pyrroline-5-carboxylate reductase 1,	P5CR1_HUMAN	33	kDa	P32322	Homo sapiens
	mitochondrial
150	Ig lambda chain V-I region WAH	LV106_HUMAN	12	kDa	P04208	Homo sapiens
151	Zinc finger and BTB domain-	ZBT10_HUMAN	92	kDa	Q96DT7	Homo sapiens
	containing protein 10
152	Cystatin-C	CYTC_HUMAN	16	kDa	P01034	Homo sapiens
153	Major vault protein	MVP_HUMAN	99	kDa	Q14764	Homo sapiens
154	Phosphatidylcholine-sterol	LCAT_HUMAN	50	kDa	P04180	Homo sapiens
	acyltransferase
155	Sulfhydryl oxidase 1	QSCN6_HUMAN	83	kDa	O00391	Homo sapiens
156	Far upstream element-binding	FUBP3_HUMAN	62	kDa	Q96I24	Homo sapiens
	protein 3
157	Ig delta chain C region	IGHD_HUMAN	42	kDa	P01880	Homo sapiens
158	Plasma serine protease inhibitor	IPSP_HUMAN	46	kDa	P05154	Homo sapiens
159	Heterogeneous nuclear	HNRPR_HUMAN	71	kDa	O43390	Homo sapiens
	ribonucleoprotein R
160	Hemoglobin subunit gamma-1	HBG1_HUMAN	16	kDa	P69891	Homo sapiens
		(+1)
161	TAR DNA-binding protein 43	TADBP_HUMAN	45	kDa	Q13148	Homo sapiens
162	Neural cell adhesion molecule L1-	CHL1_HUMAN	135	kDa	O00533	Homo sapiens
	like protein
163	Bifunctional polynucleotide	PNKP_HUMAN	57	kDa	Q96T60	Homo sapiens
	phosphatase/kinase
164	Fibrocystin	PKHD1_HUMAN	447	kDa	Q8TCZ9	Homo sapiens
165	Heterogeneous nuclear	ROAA_HUMAN	36	kDa	Q99729	Homo sapiens
	ribonucleoprotein A/B
166	Peroxiredoxin-1	PRDX1_HUMAN	22	kDa	Q06830	Homo sapiens
167	40S ribosomal protein S16	RS16_HUMAN	16	kDa	P62249	Homo sapiens
168	Heat shock 70 kDa protein 1	HSP71_HUMAN	70	kDa	P08107	Homo sapiens
169	40S ribosomal protein S25	RS25_HUMAN	14	kDa	P62851	Homo sapiens
170	Fetuin-B	FETUB_HUMAN	42	kDa	Q9UGM5	Homo sapiens
171	Transferrin receptor protein 1	TFR1_HUMAN	85	kDa	P02786	Homo sapiens
172	Myelin basic protein	MBP_HUMAN	33	kDa	P02686	Homo sapiens
173	Aldo-keto reductase family 1	AK1C1_HUMAN	37	kDa	Q04828	Homo sapiens
	member C1
174	Uncharacterized protein C19orf21	CS021_HUMAN	75	kDa	Q8IVT2	Homo sapiens
175	TATA-binding protein-associated	RBP56_HUMAN	62	kDa	Q92804	Homo sapiens
	factor 2N
176	ATP-dependent DNA helicase 2	KU86_HUMAN	83	kDa	P13010	Homo sapiens
	subunit 2
177	Sulfide:quinone oxidoreductase,	SQRD_HUMAN	50	kDa	Q9Y6N5	Homo sapiens
	mitochondrial
178	Interleukin enhancer-binding factor	ILF2_HUMAN	43	kDa	Q12905	Homo sapiens
	2
179	Prostaglandin F2-alpha receptor	PF2R_HUMAN	40	kDa	P43088	Homo sapiens
180	Peptidase inhibitor 16	PI16_HUMAN	49	kDa	Q6UXB8	Homo sapiens
181	Actin, alpha cardiac muscle 1	ACTC_HUMAN	42	kDa	P68032	Homo sapiens
182	E3 SUMO-protein ligase RanBP2	RBP2_HUMAN	358	kDa	P49792	Homo sapiens
	Mitochondrial import inner
	membrane translocase subunit
183	TIM50	TIM50_HUMAN	40	kDa	Q3ZCQ8	Homo sapiens
184	Heterogeneous nuclear	HNRPD_HUMAN	38	kDa	Q14103	Homo sapiens
	ribonucleoprotein D0
185	Interleukin enhancer-binding factor	ILF3_HUMAN	95	kDa	Q12906	Homo sapiens
	3
186	Heterogeneous nuclear	HNRPG_HUMAN	42	kDa	P38159	Homo sapiens
	ribonucleoprotein G
187	40S ribosomal protein S4, X isoform	RS4X_HUMAN	30	kDa	P62701	Homo sapiens
188	Caspase-14	CASPE_HUMAN	28	kDa	P31944	Homo sapiens
189	Annexin A2	ANXA2_HUMAN	39	kDa	P07355	Homo sapiens
190	Isocitrate dehydrogenase [NAD]	IDH3A_HUMAN	40	kDa	P50213	Homo sapiens
	subunit alpha, mitochondrial
191	Cysteine-rich secretory protein 3	CRIS3_HUMAN	28	kDa	P54108	Homo sapiens
192	Myeloperoxidase	PERM_HUMAN	84	kDa	P05164	Homo sapiens
193	Transformation/transcription	TRRAP_HUMAN	438	kDa	Q9Y4A5	Homo sapiens
	domain-associated protein
194	Isocitrate dehydrogenase [NAD]	IDH3B_HUMAN	42	kDa	043837	Homo sapiens
	subunit beta, mitochondrial
195	Collagen alpha-2(V) chain	CO5A2_HUMAN	145	kDa	P05997	Homo sapiens
196	Baculoviral IAP repeat-containing	BIRC6_HUMAN	528	kDa	Q9NR09	Homo sapiens
	protein 6
197	Bleomycin hydrolase	BLMH_HUMAN	53	kDa	Q13867	Homo sapiens
198	Poly(rC)-binding protein 1	PCBP1_HUMAN	37	kDa	Q15365	Homo sapiens
199	Tubulin beta-3 chain	TBB3_HUMAN	50	kDa	Q13509	Homo sapiens
200	60 kDa heat shock protein,	CH60_HUMAN	61	kDa	P10809	Homo sapiens
	mitochondrial
201	ATP synthase subunit beta,	ATPB_HUMAN	57	kDa	P06576	Homo sapiens
	mitochondrial
202	40S ribosomal protein S18	RS18_HUMAN	18	kDa	P62269	Homo sapiens
203	DnaJ homolog subfamily A member	DNJA1_HUMAN	45	kDa	P31689	Homo sapiens
	1
204	RNA-binding motif, single-stranded-	RBMS1_HUMAN	45	kDa	P29558	Homo sapiens
	interacting protein 1
205	40S ribosomal protein S19	RS19_HUMAN	16	kDa	P39019	Homo sapiens
206	Tubulin alpha-1 chain	TBA1_HUMAN	50	kDa	P68366	Homo sapiens
207	Protein Hook homolog 1	HOOK1_HUMAN	85	kDa	Q9UJC3	Homo sapiens
208	Brother of CDO	BOC_HUMAN	121	kDa	Q9BWV1	Homo sapiens
209	Signal recognition particle 54 kDa	SRP54_HUMAN	56	kDa	P61011	Homo sapiens
	protein
210	Trinucleotide repeat-containing 6B	TNC6B_HUMAN	194	kDa	Q9UPQ9	Homo sapiens
	protein
211	Aldehyde dehydrogenase, dimeric	AL3A1_HUMAN	50	kDa	P30838	Homo sapiens
	NADP-preferring
212	40S ribosomal protein S3	RS3_HUMAN	27	kDa	P23396	Homo sapiens
213	Fatty aldehyde dehydrogenase	AL3A2_HUMAN	55	kDa	P51648	Homo sapiens
214	Electron transfer flavoprotein	ETFA_HUMAN	35	kDa	P13804	Homo sapiens
	subunit alpha, mitochondrial
215	RNA-binding protein EWS	EWS_HUMAN	68	kDa	Q01844	Homo sapiens
216	Histone H2A.V	H2AV_HUMAN	14	kDa	Q71UI9	Homo sapiens
	Heterogeneous nuclear	(+1)
217	ribonucleoprotein Q	HNRPQ_HUMAN	70	kDa	O60506	Homo sapiens
218	Pyrroline-5-carboxylate reductase	P5CR2_HUMAN	34	kDa	Q96C36	Homo sapiens
219	Prohibitin	PHB_HUMAN	30	kDa	P35232	Homo sapiens
220	RuvB-like 1	RUVB1_HUMAN	50	kDa	Q9Y265	Homo sapiens
221	Protein-glutamine gamma-	TGM2_HUMAN	77	kDa	P21980	Homo sapiens
	glutamyltransferase
222	Ubiquitin-associated protein 2	UBAP2_HUMAN	117	kDa	Q5T6F2	Homo sapiens
223	Latent-transforming growth factor	LTB1L_HUMAN	187	kDa	Q14766	Homo sapiens
	beta-binding protein 1
224	Thioredoxin domain-containing	TXND2_HUMAN	60	kDa	Q86VQ3	Homo sapiens
	protein 2
225	Leucine-rich repeat-containing	LRC17_HUMAN	52	kDa	Q8N6Y2	Homo sapiens
	protein 17
226	Protein FAM105B	F105B_HUMAN	40	kDa	Q96BN8	Homo sapiens
227	Myosin-Ia	MYO1A_HUMAN	118	kDa	Q9UBC5	Homo sapiens
	Ras GTPase-activating-like protein
228	IQGAP2	IQGA2_HUMAN	181	kDa	Q13576	Homo sapiens
229	26Sproteasome non-ATPase	PSMD1_HUMAN	102	kDa	Q99460	Homo sapiens
	regulatory subunit 1
230	Actin, alpha skeletal muscle	ACTS_HUMAN	42	kDa	P68133	Homo sapiens
231	Cleavage stimulation factor subunit	CSTF3_HUMAN	83	kDa	Q12996	Homo sapiens
	3
232	Clusterin	CLUS_HUMAN	52	kDa	P10909	Homo sapiens
233	Fibrocystin-L	PKHL1_HUMAN	466	kDa	Q86WI1	Homo sapiens
234	InaD-like protein	INADL_HUMAN	196	kDa	Q8NI35	Homo sapiens
235	Keratin, type I cuticular Ha1	K1H1_HUMAN	47	kDa	Q15323	Homo sapiens
236	Keratin, type I cuticular Ha2	K1H2_HUMAN	50	kDa	Q14532	Homo sapiens
237	Keratin, type I cuticular Ha6	K1H6_HUMAN	52	kDa	O76013	Homo sapiens
238	Keratin, type I cytoskeletal 10	K1C10_HUMAN	59	kDa	P13645	Homo sapiens
239	Keratin, type I cytoskeletal 14	K1C14_HUMAN	52	kDa	P02533	Homo sapiens
240	Keratin, type I cytoskeletal 16	K1C16_HUMAN	51	kDa	P08779	Homo sapiens
241	Keratin, type I cytoskeletal 18	K1C18_HUMAN	48	kDa	P05783	Homo sapiens
242	Keratin, type I cytoskeletal 19	K1C19_HUMAN	44	kDa	P08727	Homo sapiens
243	Keratin, type I cytoskeletal 9	K1C9_HUMAN	62	kDa	P35527	Homo sapiens
244	Keratin, type II cuticular Hb1	KRT81_HUMAN	55	kDa	Q14533	Homo sapiens
245	Keratin, type II cuticular Hb5	KRT85_HUMAN	56	kDa	P78386	Homo sapiens
246	Keratin, type II cytoskeletal 1	K2C1_HUMAN	66	kDa	P04264	Homo sapiens
247	Keratin, type II cytoskeletal 1b	K2C1B_HUMAN	62	kDa	Q7Z794	Homo sapiens
248	Keratin, type II cytoskeletal 2	K22E_HUMAN	65	kDa	P35908	Homo sapiens
	epidermal
249	Keratin, type II cytoskeletal 4	K2C4_HUMAN	57	kDa	P19013	Homo sapiens
250	Keratin, type II cytoskeletal 5	K2C5_HUMAN	62	kDa	P13647	Homo sapiens
251	Keratin, type II cytoskeletal 6B	K2C6B_HUMAN	60	kDa	P04259	Homo sapiens
252	Keratin, type II cytoskeletal 7	K2C7_HUMAN	51	kDa	P08729	Homo sapiens
253	Keratin, type II cytoskeletal 8	K2C8_HUMAN	54	kDa	P05787	Homo sapiens
254	Lymphoid-restricted membrane	LRMP_HUMAN	62	kDa	Q12912	Homo sapiens
	protein
255	Myosin light chain 1, skeletal muscle	MLE1_HUMAN	21	kDa	P05976	Homo sapiens
	isoform
256	Myosin-2	MYH2_HUMAN	223	kDa	Q9UKX2	Homo sapiens
257	Protein Shroom3	SHRM3_HUMAN	216	kDa	Q8TF72	Homo sapiens
258	Ras-related GTP-binding protein A	RRAGA_HUMAN	37	kDa	Q7L523	Homo sapiens
259	Sushi, nidogen and EGF-like	SNED1_HUMAN	152	kDa	Q8TER0	Homo sapiens
	domain-containing protein 1
260	Retinol-binding protein 4	RET4_HUMAN	23	kDa	P02753	Homo sapiens

TABLE 2

Proteins identified in spent media of human embryos. *

SEQID			Protein Molecular	Accession	Day of Embryo	Nature of
NO.	Protein Name	Entry Name	Weight	Number	Development	Viability Marker

261	14-3-3 protein zeta/delta	1433Z_HUMAN	28	kDa	P63104	D 1
262	6-phosphofructokinase, muscle	K6PF_HUMAN	85	kDa	P08237	D 1
	type, isoform 1
263	6-phosphofructokinase, muscle	K6PF_HUMAN	82	kDA	P08237-2	D 1
	type, isoform 1
264	Adenylate kinase isoenzyme 1	KAD1_HUMAN	22	kDa	P00568	D 1
265	Alpha-actinin-2	ACTN2_HUMAN	104	kDa	P35609	D 1
266	Beta-enolase, isoform 1	ENOB_HUMAN	47	kDa	P13929	D 1
267	Beta-enolase, isoform 2	ENOB_HUMAN	44	kDa	P13929-2	D 1
268	Beta-enolase, isoform 3	ENOB_HUMAN	42	kDa	P13929-3	D 1
269	Creatine kinase M-type	KCRM_HUMAN	43	kDa	P06732	D 1
270	Fructose-bisphosphate aldolase A	ALDOA_HUMAN	39	kDa	P04075	D 1
271	Glycogen phosphorylase, muscle form	PYGM_HUMAN	97	kDa	P11217	D 1
272	L-lactate dehydrogenase A chain	LDHA_HUMAN	37	kDa	P00338	D 1
273	Myosin-1	MYH1_HUMAN	223	kDa	P12882	D 1
274	Myosin-2	MYH2_HUMAN	223	kDa	Q9UKX2	D 1
275	Myosin-3	MYH3_HUMAN	224	kDa	P11055	D 1
276	Myosin-4	MYH4_HUMAN	223	kDa	Q9Y623	D 1
277	Myosin-6	MYH6_HUMAN	224	kDa	P13533	D 1
278	Myosin-7	MYH7_HUMAN	223	kDa	P12883	D 1
279	Myosin-8	MYH8_HUMAN	223	kDa	P13535	D 1
280	Phosphoglucomutase-1, isoform 1	PGM1_HUMAN	61	kDa	P36871	D 1
281	Phosphoglucomutase-1, isoform 2	PGM1_HUMAN	64	kDa	P36871-2	D 1
282	Phosphoglycerate kinase 1	PGK1_HUMAN	45	kDa	P00558	D 1
283	Phosphoglycerate mutase 1	PGAM1_HUMAN	29	kDa	P18669	D 1
284	Pyruvate kinase isozyme M2	KPYM_HUMAN	58	kDa	P14618	D 1
285	Pyruvate kinase isozyme M1	KPYM_HUMAN	58	kDa	P14618-2	D 1
286	Sarcoplasmic/endoplasmic reticulum	AT2A1_HUMAN	110	kDa	O14983	D 1
	calcium ATPase 1, Isoform SERCA1B
287	Sarcoplasmic/endoplasmic reticulum	AT2A1_HUMAN	109	kDa	O14983-2	D 1
	calcium ATPase 1, Isoform SERCA1A
288	Sarcoplasmic/endoplasmic reticulum	AT2A2_HUMAN	115	kDa	P16615	D 1
	calcium ATPase 2, isoform 1
289	Sarcoplasmic/endoplasmic reticulum	AT2A2_HUMAN	110	kDa	P16615-2	D 1
	calcium ATPase 2, isoform 2
290	Sarcoplasmic/endoplasmic reticulum	AT2A2_HUMAN	110	kDa	P16615-3	D 1
	calcium ATPase 2, isoform 3
291	Sarcoplasmic/endoplasmic reticulum	AT2A2_HUMAN	112	kDa	P16615-4	D 1
	calcium ATPase 2, isoform 4
292	Sarcoplasmic/endoplasmic reticulum	AT2A2_HUMAN	110	kDa	P16615-5	D 1
	calcium ATPase 2, isoform 5
293	Triosephosphate isomerase, isoform 1	TPIS_HUMAN	27	kDa	P60174	D 1
294	Triosephosphate isomerase, isoform 2	TPIS_HUMAN	27	kDa	P60174-2\|	D 1
295	Tropomyosin alpha-1 chain, isoform 1	TPM1_HUMAN	33	kDa	P09493	D 1
296	Tropomyosin alpha-1 chain, isoform 2	TPM1_HUMAN	27	kDa	P09493-2	D 1
297	Tropomyosin alpha-1 chain, isoform 3	TPM1_HUMAN	33	kDa	P09493-3	D 1
298	Tropomyosin alpha-1 chain, isoform 4	TPM1_HUMAN	33	kDa	P09493-4	D 1
299	Tropomyosin alpha-1 chain, isoform 5	TPM1_HUMAN	28	kDa	P09493-6	D 1
300	Tropomyosin alpha-3 chain, isoform 1	TPM3_HUMAN	33	kDa	P06753	D 1
301	Tropomyosin alpha-3 chain, isoform 2	TPM3_HUMAN	29	kDa	P06753-2	D 1
302	Tropomyosin alpha-3 chain, isoform 3	TPM3_HUMAN	29	kDa	P06753-3	D 1
303	Collagen alpha-1(I) chain	CO1A1_HUMAN	139	kDa	P02452	D 1/D 3
304	Cystatin-A	CYTA_HUMAN	11	kDa	P01040	D 1/D 3
305	Filaggrin	FILA_HUMAN	435	kDa	P20930	D 1/D 3
306	Keratinocyte proline-rich protein	KPRP_HUMAN	64	kDa	Q5T749	D 1/D 3
307	Selenium-binding protein 1, isoform 1	SBP1_HUMAN	52	kDa	Q13228	D 3
308	Selenium-binding protein 1, isoform 2	SBP1_HUMAN	45	kDa	Q13228-2	D 3
309	Fatty acid-binding protein, epidermal	FABP5_HUMAN	15	kDa	Q01469	D 1/D 3/D 5
310	Galectin-7	LEG7_HUMAN	15	kDa	P47929	D 1/D 3/D 5	Increased with
							implantation
							Success
311	Ubiquitin	UBIQ_HUMAN	X	kDa	P02248	D 1/D 3/D 5	Increased with
							implantation
							Success
312	Calmodulin-like protein 5	CALL5_HUMAN	16	kDa	Q9NZT1	D 1/D 3/D 5
313	14-3-3 protein sigma	1433S_HUMAN	28	kDa	P31947	D 1/D 3/D 5	Increased with
							implantation
							Success
314	Histone H2A type 1-A	H2A1A_HUMAN	14	kDa	Q96QV6	D 1/D 3/D 5
315	Histone H3.1t	H31T_HUMAN	16	kDa	Q16695	D 1/D 3/D 5
316	Histone H1.3	H13_HUMAN	22	kDa	P16402	D 3/D 5
317	Lysozyme C	LYSC_HUMAN	17	kDa	P61626	D 3/D 5	Increased with
							Aneuploidy
318	Plakophilin-1, isoform 2	PKP1_HUMAN	83	kDa	Q13835	D 3/D 5	Increased with
							implantation
							Success
319	Plakophilin-1, isoform 1	PKP1_HUMAN	80	kDa	Q13835-2	D 3/D 5	Increased with
							implantation
							Success
320	Abhydrolase domain-containing	AB12B_HUMAN	41	kDa	Q7Z5M8	D 3/D 5
	protein 12B, isoform 1
321	Abhydrolase domain-containing	AB12B_HUMAN	32	kDa	Q7Z5M8-2	D 3/D 5
	protein 12B, isoform 2
322	Abhydrolase domain-containing	AB12B_HUMAN	29	kDa	Q7Z5M8-3	D 3/D 5
	protein 12B, isoform 3
323	Abhydrolase domain-containing	AB12B_HUMAN	13	kDa	Q7Z5M8-4	D 3/D 5
	protein 12B, isoform 4
324	Abhydrolase domain-containing	AB12B_HUMAN	25	kDa	Q7Z5M8-5	D 3/D 5
	protein 12B, isoform 5
325	40S ribosomal protein SA	RSSA_HUMAN	33	kDa	P08865	D 5
326	Arginase-1, isoform 1	ARGI1_HUMAN	35	kDa	P05089	D 5
327	Arginase-1, isoform 2	ARGI1_HUMAN	36	kDa	P05089-2	D 5
328	Arginase-1, isoform 3	ARGI1_HUMAN	25	kDa	P05089-3	D 5
329	Beta-2-microglobulin	B2MG_HUMAN	14	kDa	P61769	D 5
330	Carbonic anhydrase 2	CAH2_HUMAN	29	kDa	P00918	D 5
331	Carboxypeptidase A4	CBPA4_HUMAN	47	kDa	Q9UI42	D 5
332	Catalase	CATA_HUMAN	60	kDa	P04040	D 5
333	Cathepsin D	CATD_HUMAN	45	kDa	P07339	D 5
334	CD44 antigen, isoform 1	CD44_HUMAN	81	kDa	P16070	D 5	Increased with
							implantation
							Success
335	CD44 antigen, isoform 2	CD44_HUMAN	3	kDa	P16070-2	D 5	Increased with
							implantation
							Success
336	CD44 antigen, isoform 3	CD44_HUMAN	78	kDa	P16070-3	D 5	Increased with
							implantation
							Success
337	CD44 antigen, isoform 4	CD44_HUMAN	77	kDa	P16070-4	D 5	Increased with
							implantation
							Success
338	CD44 antigen, isoform 5	CD44_HUMAN	81	kDa	P16070-5	D 5	Increased with
							implantation
							Success
339	CD44 antigen, isoform 6	CD44_HUMAN	77	kDa	P16070-6	D 5	Increased with
							implantation
							Success
340	CD44 antigen, isoform 7	CD44_HUMAN	78	kDa	P16070-7	D 5	Increased with
							implantation
							Success
341	CD44 antigen, isoform 8	CD44_HUMAN	74	kDa	P16070-8	D 5	Increased with
							implantation
							Success
342	CD44 antigen, isoform 9	CD44_HUMAN	74	kDa	P16070-9	D 5	Increased with
							implantation
							Success
343	CD44 antigen, isoform 10	CD44_HUMAN	53	kDa	P16070-10	D 5	Increased with
							implantation
							Success
344	CD44 antigen, isoform 11	CD44_HUMAN	47	kDa	P16070-11	D 5	Increased with
							implantation
							Success
345	CD44 antigen, isoform 12	CD44_HUMAN	39	kDa	P16070-12	D 5	Increased with
							implantation
							Success
346	CD44 antigen, isoform 13	CD44_HUMAN	46	kDa	P16070-13	D 5	Increased with
							implantation
							Success
347	CD44 antigen, isoform 14	CD44_HUMAN	43	kDa	P16070-14	D 5	Increased with
							implantation
							Success
348	CD44 antigen, isoform 15	CD44_HUMAN	32	kDa	P16070-15	D 5	Increased with
							implantation
							Success
349	CD44 antigen, isoform 16	CD44_HUMAN	73	kDa	P16070-16	D 5	Increased with
							implantation
							Success
350	CD44 antigen, isoform 17	CD44_HUMAN	76	kDa	P16070-17	D 5	Increased with
							implantation
							Success
351	Creatine kinase B-type	KCRB_HUMAN	43	kDa	P12277	D 5
352	Dermokine, isoform 1	DMKN_HUMAN	47	kDa	Q6E0U4	D 5
353	Dermokine, isoform 2	DMKN_HUMAN	47	kDa	Q6E0U4-2	D 5
354	Dermokine, isoform 3	DMKN_HUMAN	37	kDa	Q6E0U4-3	D 5
355	Dermokine, isoform 4	DMKN_HUMAN	45	kDa	Q6E0U4-4	D 5
356	Dermokine, isoform 5	DMKN_HUMAN	38	kDa	Q6E0U4-5	D 5
357	Dermokine, isoform 6	DMKN_HUMAN	42	kDa	Q6E0U4-6	D 5
358	Dermokine, isoform 7	DMKN_HUMAN	35	kDa	Q6E0U4-7	D 5
359	Dermokine, isoform 8	DMKN_HUMAN	20	kDa	Q6E0U4-8	D 5
360	Dermokine, isoform 9	DMKN_HUMAN	19	kDa	Q6E0U4-9	D 5
361	Dermokine, isoform 10	DMKN_HUMAN	17	kDa	Q6E0U4-10	D 5
362	Dermokine, isoform 11	DMKN_HUMAN	15	kDa	Q6E0U4-11	D 5
363	Dermokine, isoform 12	DMKN_HUMAN	16	kDa	Q6E0U4-12	D 5
364	Dermokine, isoform 13	DMKN_HUMAN	14	kDa	Q6E0U4-13	D 5
365	Dermokine, isoform 14	DMKN_HUMAN	15	kDa	Q6E0U4-14	D 5
366	Dermokine, isoform 15	DMKN_HUMAN	10	kDa	Q6E0U4-15	D 5
367	Extracellular glycoprotein lacritin	LACRT_HUMAN	14	kDa	Q9GZZ8	D 5
368	Ferritin light chain (Ferritin L	FRIL_HUMAN	20	kDa	P02792	D 5	Increased with
	subunit)						implantation
							Success
369	Fibrinogen gamma chain, isoform	FIBG_HUMAN	52	kDa	P02679	D 5
	gamma-B
370	Fibrinogen gamma chain, isoform	FIBG_HUMAN	49	kDa	P02679-2	D 5
	gamma-A
371	Gamma-enolase	ENOG_HUMAN	47	kDa	P09104	D 5	Increased with
							implantation
							Success
372	Gamma-glutamylcyclotransferase,	GGCT_HUMAN	21	kDa	O75223	D 5
	isoform 1
373	Gamma-glutamylcyclotransferase,	GGCT_HUMAN	13	kDa	O75223-2	D 5
	isoform 2
374	Heat shock protein beta-1	HSPB1_HUMAN	23	kDa	P04792	D 5	Increased with
							implantation
							Success
375	Histidine ammonia-lyase	HUTH_HUMAN	73	kDa	P42357	D 5
376	Ig mu chain C region, isoform 1	IGHM_HUMAN	49	kDa	P01871	D 5
377	Ig mu chain C region, isoform 2	IGHM_HUMAN	52	kDa	P01871-2	D 5
378	Interleukin-1 family member 7	IL1F7_HUMAN	224	kDa	Q9NZH6	D 5
	precursor, isoform B
379	Interleukin-1 family member 7	IL1F7_HUMAN	22	kDa	Q9NZH6-2	D 5
	precursor, isoform A
380	Interleukin-1 family member 7	IL1F7_HUMAN	20	kDa	Q9NZH6-2	D 5
	precursor, isoform C
381	Interleukin-1 family member 7	IL1F7_HUMAN	22	kDa	Q9NZH6-2	D 5
	precursor, isoform D
382	Interleukin-1 family member 7	IL1F7_HUMAN	17	kDa	Q9NZH6-2	D 5
	precursor, isoform E
383	Lipocalin-1	LCN1_HUMAN	19	kDa	P31025	D 5	Increased with
							Aneuploidy
384	Methionine synthase	METH_HUMAN	141	kDa	Q99707	D 5
385	Peroxiredoxin-2	PRDX2_HUMAN	22	kDa	P32119	D 5
386	Proprotein convertase	PCSK9_HUMAN	74	kDa	Q8NBP7	D 5
	subtilisin/kexin type 9, isoform 1
387	Proprotein convertase	PCSK9_HUMAN	21	kDa	Q8NBP7-2	D 5
	subtilisin/kexin type 9, isoform 2
388	Protein POF1B, isoform 1	POF1B_HUMAN	69	kDa	Q8WVV4	D 5
389	Protein POF1B, isoform 2	POF1B_HUMAN	68	kDa	Q8WVV4-2	D 5
390	Protein POF1B, isoform 3	POF1B_HUMAN	35	kDa	Q8WVV4-3	D 5
391	Protein S100-A7	S10A7_HUMAN	11	kDa	P31151	D 5	Increased with
							implantation
							Success
392	Protein-glutamine gamma-	TGM3_HUMAN	77	kDa	Q08188	D 5
	glutamyltransferase E
393	Pyruvate kinase isozymes M1/M2,	KPYM_HUMAN	58	kDa	P14618	D 5
	isoform M2
394	Pyruvate kinase isozymes M1/M2,	KPYM_HUMAN	58	kDa	P14618-2	D 5
	isoform M1
395	Receptor-type tyrosine-protein	PTPRG_HUMAN	162	kDa	P23470	D 5
	phosphatase gamma, isoform 1
396	Receptor-type tyrosine-protein	PTPRG_HUMAN	159	kDa	P23470-2	D 5
	phosphatase gamma, isoform 2
397	Serine protease inhibitor Kazal-type	ISK5_HUMAN	121	kDa	Q9NQ38	D 5	Increased with
	5, isoform f1						implantation
							Success
398	Serine protease inhibitor Kazal-type	ISK5_HUMAN	104	kDa	Q9NQ38	D 5	Increased with
	5, isoform short						implantation
							Success
399	Serine protease inhibitor Kazal-type	ISK5_HUMAN	124	kDa	Q9NQ38	D 5	Increased with
	5, isoform long						implantation
							Success
400	Serpin B3, isoform 1	SPB3_HUMAN	45	kDa	P29508	D 5
401	Serpin B3, isoform 2	SPB3_HUMAN	39	kDa	P29508-2	D 5
402	Uteroglobin	UTER_HUMAN	10	kDa	P11684	D 5	Increased with
							implantation
							Success
403	V-set and immunoglobulin domain-	VSIG8_HUMAN	44	kDa	Q5VU13	D 5	Increased with
	containing protein 8, isoform 1						implantation
							Success
404	V-set and immunoglobulin domain-	VSIG8_HUMAN	25	kDa		D 5	Increased with
	containing protein 8, isoform 1						implantation
							Success

* All Proteins are from Homo Sapiens

Example 2

Secretome Profiling to Predict Implantation Potential of a Human Embryo

The following nonlimiting example teaches by way of illustration, not by limitation, the fabrication and employment of a customized immunoassay test kit for secretome profiling of a human embryo. Immunoassay test kit fabrication occurs by modifying the well surfaces of a 96-well microtiter plate. Each separate well of the microtiter plate is incubated with an unlabelled capture antibody that recognizes one specific protein from the secretome panel. Custom capture antibodies are purchased from Rockland Immunochemicals, Inc. After incubation for 12 hours at 4° C., capture antibodies passively adsorb to the well surface. Subsequently, all wells of the 96-well plate are washed three times with a buffer comprising 1× phosphate buffer saline and 0.1% Tween-20 (PBST), blocked with 1% bovine serum albumin (BSA) for 1 hour at ambient temperature and washed three times with PBST.
Human cleavage-stage embryos are cultured in 10 μL drops of G1 supplemented with 2.5 mg/mL recombinant albumin under oil at 37° C., 6% CO₂, 5% O₂for 24 hours. The embryos are washed twice in G2 culture media and further cultured in 10 μL, drops of G2 supplemented with 2.5 mg/mL recombinant albumin under oil at 37° C., 6% CO₂, 5% O₂for 48 hours with a fresh drop of G2 media added after 24 hours. Spent media samples of blastocysts are transferred into 0.65 mL Eppendorf tubes. Control groups comprise media cultured and collected under the same conditions but without embryos.
Secretome profiling proceeds using spent media culture in a sandwich ELISA format. The spent media culture is diluted into phosphate buffer saline (PBS) buffer and further distributed to separate wells of said customized microtiter plate. After incubation for one hour at room temperature, the samples are aspirated and all wells are washed four times with PBST buffer. Primary antibodies, each recognizing a distinct protein from the secretome panel, are distributed into wells that correspond to appropriate capture antibodies and permitted to incubate for one hour at room temperature. The wells are washed four times with PBST and incubated with a secondary antibody conjugated with an enzyme. The term “secondary antibody” refers to an antibody that binds to primary antibodies and may be conjugated with detection probes such as enzymes or fluorophores. In one embodiment, the secondary antibody contains the horseradish peroxidase (HRP) enzyme that converts the chromogenic substrate, 3,3′,5,5′-tetramethylbenzidene (TMB), into a blue product quantified at 655 nm on a spectrophotometer. In another embodiment, the HRP enzymatic reaction is stopped with a solution containing sulfuric acid and quantified at 450 nm.
In one embodiment, secretome profiling of a secretome panel of 261 individual proteins (Table 1), each selected for significant developmental competence and implantation potential, are monitored using said ELISA immunoassay test kit. In another embodiment, secretome profiling of a secretome panel comprising 37 proteins (Table 2) are monitored using said ELISA immunoassay test kit. Secretome profiling of the 37 individual proteins (Table 2) from spent media of human embryos correlates with embryonic viability and euploidy.
Changes may be made in the above methods and systems without departing from the scope hereof. It should be noted that the matter contained in the above description or shown in the accompanying drawings should be interpreted as illustrative and not in a limiting sense. The following claims are intended to cover all generic and specific features described herein, as well as all statements of the scope of the present method and system and reasonable variations thereof, which, as a matter of language, might be said to fall therebetween.

Claims

1. A system for enhancing the pregnancy success rate of in vitro fertilization, comprising:

means for determining the secretome profile of an embryo to identify proteins implicated in implantation success; and

means for recommending whether to implant the embryo on the basis of the secretome profile.

2. The system of claim 1, further comprising data representative of a secretome profile of an embryo acquired by ELISA.

3. The system of claim 2, further comprising the secretome profile of an embryo acquired using a secretome panel selected from the group consisting of SEQ ID Nos. 1-403.

4. The system of claim 3, further comprising the secretome profile of an embryo acquired using a secretome panel selected as one or more members of the group consisting of SEQ ID Nos. 1-404.

5. The system of claim 3, further comprising the secretome profile of an embryo acquired using a secretome panel selected as one or more members of the group consisting of SEQ ID Nos. 261-404.

6. The system of claim 3, further comprising the secretome profile of an embryo acquired using a secretome panel selected as one or more members of the group consisting of SEQ ID Nos. 310, 311, 313, 317, 318, 319, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 345, 346, 347, 348, 349, 350, 368, 371, 374, 383, 391, 397, 398, 399, 402, 403, and 404.

7. The system of claim 3, further comprising the secretome profile of an embryo acquired using a secretome panel selected as one or more members of the group consisting of SEQ ID Nos. 310, 311, 313, 318, 319, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 345, 346, 347, 348, 349, 350, 368, 371, 374, 391, 397, 398, 399, 402, 403, and 404.

8. The system of claim 3, further comprising the secretome profile of an embryo acquired using a secretome panel selected as one or more members of the group consisting of SEQ ID Nos. 317 and 383.

9. The system of claim 1, further comprising the secretome profile of an embryo acquired using a secretome panel selected as one or more members of the group consisting of SEQ ID Nos. 1-404.

10. The system of claim 1, further comprising the secretome profile of an embryo acquired using a secretome panel selected as one or more members of the group consisting of SEQ ID Nos. 261-404.

11. The system of claim 1, further comprising the secretome profile of an embryo acquired using a secretome panel selected as one or more members of the group consisting of SEQ ID Nos. 310, 311, 313, 317, 318, 319, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 345, 346, 347, 348, 349, 350, 368, 371, 374, 383, 391, 397, 398, 399, 402, 403, and 404.

12. The system of claim 1, further comprising the secretome profile of an embryo acquired using a secretome panel selected as one or more members of the group consisting of SEQ ID Nos. 310, 311, 313, 318, 319, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 345, 346, 347, 348, 349, 350, 368, 371, 374, 391, 397, 398, 399, 402, 403, and 404.

13. The system of claim 1, further comprising the secretome profile of an embryo acquired using a secretome panel selected as one or more members of the group consisting of SEQ ID Nos. 317 and 383.

14. A method of in vitro fertilization, comprising:

determining the secretome profile of a candidate embryo to ascertain proteins implicated in implantation success;

modeling on basis of the secretome profile to assess candidate embryo viability for

recommending whether to implant the candidate embryo on the basis of the viability assessment; and

conditionally implanting the candidate embryo on the basis of the recommendation.

15. The method of claim 14, wherein the step of determining the secretome profile includes using a secretome panel selected as one or more members of the group consisting of SEQ ID Nos. 1-404.

16. The method of claim 14, wherein the step of determining the secretome profile includes using a secretome panel selected as one or more members of the group consisting of SEQ ID Nos. 261-404.

17. The method of claim 14, wherein the step of determining the secretome profile includes using a secretome panel selected as one or more members of the group consisting of SEQ ID Nos. 310, 311, 313, 317, 318, 319, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 345, 346, 347, 348, 349, 350, 368, 371, 374, 383, 391, 397, 398, 399, 402, 403, and 404.

18. The method of claim 14, wherein the step of determining the secretome profile includes using a secretome panel selected as one or more members of the group consisting of SEQ ID Nos. 310, 311, 313, 318, 319, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 345, 346, 347, 348, 349, 350, 368, 371, 374, 391, 397, 398, 399, 402, 403, and 404.

19. The method of claim 14, wherein the step of determining the secretome profile includes using a secretome panel selected as one or more members of the group consisting of SEQ ID Nos. 317 and 383.

20. In an ELISA assay kit comprising a plurality of microwells for the quantitation of protein content in a sample, the improvement comprising:

the microwells being constructed and arranged to quantitate for a plurality of proteins selected from SEQ ID Nos. 1-404.

21. The kit claim 20, wherein the plurality of proteins are selected from the group consisting of SEQ ID Nos. 261-404.

22. The kit claim 20, wherein the plurality of proteins are selected from the group consisting of SEQ ID Nos. 310, 311, 313, 317, 318, 319, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 345, 346, 347, 348, 349, 350, 368, 371, 374, 383, 391, 397, 398, 399, 402, 403, and 404.

23. The kit claim 20, wherein the plurality of proteins are selected from the group consisting of SEQ ID Nos. 310, 311, 313, 318, 319, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 345, 346, 347, 348, 349, 350, 368, 371, 374, 391, 397, 398, 399, 402, 403, and 404.

24. The kit claim 20, wherein the plurality of proteins are selected from the group consisting of SEQ ID Nos. 317 and 383.